Bruker Acquires Prolab Instruments to Augment Multiomics Solutions
19 January 2022 - 11:00PM
Business Wire
Prolab precision pumps, autosamplers and
nano-flow to cap-LC UHPLC systems to further enhance performance
and robustness of timsTOF 4D proteomics and metabolomics
solutions
- Unique Zirconium™ nano-LC to cap-LC pump technology for 4
nL/min to 10 μL/min flow rates with split-less UHPLC
operation for optimized proteomics results
- Innovative, proprietary Zirconium Cube™ autosampler with
mobile injection unit technology for precise, ultra-low volume
injections in high sensitivity single-cell proteomics and
immunopeptidomics
- ZircoFIT™ UHPLC fittings for robust, easy-to-use nano- to
cap-LC fused silica connections to enhance chromatographic peak
shapes
- New Zirconium™ Ultra UHPLC System for cap-LC high-throughput
proteomics and metabolomics
Bruker Corporation (Nasdaq: BRKR) today
announced the acquisition of Prolab Instruments GmbH, a Swiss
technology company specialized in low-flow, high precision liquid
chromatography technology and systems. Financial terms of the
transaction were not disclosed.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220119005084/en/
Zirconium Ultra for cap-LC
high-throughput 4D proteomics and metabolomics
Established in 1988, ProLab’s innovations center around micro
and nano-UHPLC pump technology, resulting in the development of the
unique Zirconium™ split-less pump technology for flow rates from
nano-flow (4-800 nL/min) to cap-flow (1-10 µL/min) regimes. The
Zirconium™ Ultra nano- and cap-UHPLC system supports a broad range
of flow rates from 4 nL/min to 10 µL/min at 1000 bar (15,000 psi),
and is suitable for cap-LC in high-throughput proteomics and
metabolomics.
Recently, Prolab launched the innovative Zirconium Qube
autosampler with the proprietary mobile injection unit technology
that integrates the injector valve and loop, and moves to each
sample vial to minimize carry-over, thereby enabling ultra-low
volume injections with high precision. This unique high-precision
injection capability has potential to further enhance single cell
proteomics.
Leveraging nearly 30 years of experience with low flow rates and
minimized dead volumes, Prolab also offers unique Zircofit™ fused
silica connectors known for flexibility, robustness and ease of
use.
Mr. Werner Doebelin, the Founder and CEO of Prolab, said: “We
are pleased to become part of Bruker and augment the proteomics and
metabolomics workflows of high-performance mass spectrometry
systems like the timsTOF or scimaX® MRMS platforms. Our Zirconium
pump is already part of the Bruker high-performance nanoElute
system. Being part of Bruker allows us to increase the pace of
product innovation, and we are looking forward to bringing our
Mobile Injection Unit Technology to market to further improve
performance and robustness in key applications, like single cell
proteomics and lipidomics.”
Mr. Juergen Srega, the President of the Bruker CALID Group,
explained: “Given the enormous sensitivity improvements of our
timsTOF Pro 2 and timsTOF SCP mass spectrometers, our customers are
working with lower and lower sample amounts. Prolab’s innovative
mobile injector technology on the Zirconium Qube autosampler
provides high-precision, low volume injections with minimal sample
loss and carryover, as well as faster cycle times. Zirconium
perfectly complements our ultra-high sensitivity unbiased, deep 4D
proteomics, immunopeptidomics and single-cell proteomics
solutions.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220119005084/en/
Media: Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Investors: Bruker Investor Relations T: +1 (978)
663-3660, ext. 1479 E: Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024